Connect Biopharma Holdings Limited
NGM: CNTBLive Quote
About Connect Biopharma Holdings Limited
Healthcare
Biotechnology
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
📊 Fundamental Analysis
Connect Biopharma Holdings Limited demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -100.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -82.7%, which indicates that capital utilization is currently under pressure.
At a current price of $2.82, CNTB currently sits at the 69th percentile of its 52-week range (Range: $0.63 - $3.82).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
Key Financials
Market Cap
$133.48M
Trailing P/E
--
Forward P/E
-3.77
Beta (5Y)
--
52W High
$3.82
52W Low
$0.63
Avg Volume
210K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App